Orchid Pharma gets EIR report from USFDA on inspection closure
New Delhi : Orchid Pharma has received the Establishment inspection report (EIR) from the US health regulator based on the successful inspection closure for its API manufacturing facility in Tamil Nadu's Kancheepuram district.
"Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram district. The facility was inspected by USFDA in the month of August 2015," the company said in a BSE filing today.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Shares of Orchid Pharma were trading 6.84 per cent up at Rs 41.40 a piece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd